Use of cannabinoids in the treatment of multiple myeloma
US11065227B2 · kind B2 · utility
34Cited by
23References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 31, 2017 |
| Grant date | Jul 20, 2021 |
| Priority date | — |
| Expiry date | Jul 31, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the use of a combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) in the treatment of multiple myeloma. The combination of THC and CBD appears to be particularly effective in reducing cell viability and cell migration in this disease. Preferably the THC and CBD are used is in the form of a highly purified extract of cannabis such that the cannabinoids are present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, the THC and CBD may be a synthetically produced cannabinoid.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.